Therapeutic index improvement of antibody-drug conjugates
The commentary by Colombo and Rich recently published in Cancer Cell provides a timely and comprehensive review of the clinical maximum tolerated doses (MTDs) of antibody−drug conjugates (ADCs) and their corresponding small molecules/chemotherapies. The authors identified similarities between their...
Saved in:
Main Authors: | Hans-Peter Gerber, Sanjeev Gangwar, Alison Betts |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2230618 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01) -
Advancements in antibody-drug conjugates as cancer therapeutics
by: Jung Yin Fong, et al.
Published: (2025-08-01) -
Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion
by: Laura Matuszewska, et al.
Published: (2025-09-01) -
Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry
by: Tian Xu, et al.
Published: (2023-12-01) -
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
by: Kyle P. Martin, et al.
Published: (2023-12-01)